Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

281.72 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 25, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,196
Open	281.72
Bid (Size)	228.81 (300)
Ask (Size)	351.89 (100)
Prev. Close	281.72
Today's Range	281.72 - 281.72
52wk Range	157.52 - 326.63
Shares Outstanding	16,676,532
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

$100 Invested In Ligand Pharmaceuticals 10 Years Ago Would Be Worth This Much Today ↗

August 21, 2026

Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 10 years by 2.79% on an annualized basis producing an average annual return of 16.18%. Currently, Ligand Pharmaceuticals...

Via Benzinga

Ligand (LGND) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

XOMA acquisition and convertible financing boost 2026 guidance to $9.00–$9.50 per share.

Via The Motley Fool

Performance

YTD	+48.2%	+48.2%
1 Month	-5.3%	-5.3%
3 Month	+19.7%	+19.7%
6 Month	+49.1%	+49.1%
1 Year	+77.4%	+77.4%

More News

Ligand Pharmaceuticals Q2 Earnings Call Highlights ↗

August 06, 2026

Via MarketBeat

Ligand Pharmaceuticals (NASDAQ:LGND) Beats Q2 EPS Estimates, Shares Flat on In-Line Revenue ↗

August 06, 2026

Via Chartmill

Ligand Pharmaceuticals (NASDAQ:LGND) Shares Fall on Q1 Revenue and EPS Miss ↗

May 07, 2026

Via Chartmill

Ligand Pharmaceuticals (NASDAQ:LGND) Passes Minervini Trend Template and Growth Screen ↗

April 01, 2026

Via Chartmill

$100 Invested In Ligand Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗

August 05, 2026

Via Benzinga

Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets

July 14, 2026

From Ligand Pharmaceuticals

Via GlobeNewswire

XOMA Royalty Announces Closing of Its Acquisition by Ligand

July 14, 2026

From XOMA Royalty Corporation

Via GlobeNewswire

3 Overlooked Stocks Positioned for the Next Market Rotation ↗

July 13, 2026

Via MarketBeat

Ligand Pharmaceuticals Director Unloads 2,501 Shares — Should You Be Concerned? ↗

June 14, 2026

Via The Motley Fool

A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million ↗

June 07, 2026

Via The Motley Fool

Wealth Manager Sells $7 Million of Establishment Labs After Massive Gains. Is This Medical Device Stock a Buy? ↗

May 30, 2026

Via The Motley Fool

OneSpaWorld Posted Record Revenue for Last Quarter. Why Did a Fund Exit a $21.5 Million Stake? ↗

May 29, 2026

Via The Motley Fool

Is Genpact Stock a Buy After Hedge Fund Rice Hall James Raised Its Stake by $14 Million? ↗

May 19, 2026

Via The Motley Fool

Is WaterBridge Stock a Buy After Ranger Investment Raised Its Stake by 345,000 Shares? ↗

May 16, 2026

Via The Motley Fool

Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

May 12, 2026

From Orchestra BioMed Holdings, Inc.

Via GlobeNewswire

Ligand (LGND) Q1 2026 Earnings Call Transcript ↗

May 12, 2026

Via The Motley Fool

Ligand Pharmaceuticals Q1 Earnings Call Highlights ↗

May 08, 2026

Via MarketBeat

Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

May 06, 2026

From Orchestra BioMed Holdings, Inc.

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)

May 05, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

Villere St Denis Liquidates $18 Million Euronet Worldwide Stake, According to Recent SEC Filing ↗

May 04, 2026

Via The Motley Fool

Villere St Denis Dumps 134,000 Tidewater (TDW) Shares Worth $9.3 Million ↗

May 02, 2026

Via The Motley Fool

April 27, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator

April 27, 2026

From XOMA Royalty Corporation

Via GlobeNewswire

Frequently Asked Questions

Is Ligand Pharmaceuticals Incorporated - Common Stock publicly traded?

Yes, Ligand Pharmaceuticals Incorporated - Common Stock is publicly traded.

What exchange does Ligand Pharmaceuticals Incorporated - Common Stock trade on?

Ligand Pharmaceuticals Incorporated - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Ligand Pharmaceuticals Incorporated - Common Stock?

The ticker symbol for Ligand Pharmaceuticals Incorporated - Common Stock is LGND on the Nasdaq Stock Market

What is the current price of Ligand Pharmaceuticals Incorporated - Common Stock?

The current price of Ligand Pharmaceuticals Incorporated - Common Stock is 281.72

When was Ligand Pharmaceuticals Incorporated - Common Stock last traded?

The last trade of Ligand Pharmaceuticals Incorporated - Common Stock was at 08/25/26 04:00 PM ET

What is the market capitalization of Ligand Pharmaceuticals Incorporated - Common Stock?

The market capitalization of Ligand Pharmaceuticals Incorporated - Common Stock is 4.70B

How many shares of Ligand Pharmaceuticals Incorporated - Common Stock are outstanding?

Ligand Pharmaceuticals Incorporated - Common Stock has 5B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.